Table 2 Associated factors with CNS metastasis development
N = 293 | CNS Metastasis 12 months % (95% IC) | CNS Metastasis 24 months % (95% IC) | pUnivariate Analysis | RR (95% CI) | pMultivariate Analysis |
|---|---|---|---|---|---|
Age | Â | Â | Â | Â | Â |
   <60 years | 20 (14.2–25.8) | 36 (20.2–51.6) | 0.79 |  |  |
   ≥60 years | 22 (16.1–27.8) | 22 (16.1–27.8) |  |  |  |
Gender | Â | Â | Â | Â | Â |
   Female | 21 (13.6–27.3) | 31 (12.9–48.1) | 0.86 |  |  |
   Male | 22 (16.1–27.9) | 33 (18.8–46.2) |  |  |  |
Smoking History | Â | Â | Â | Â | Â |
   Negative | 24 (18.2–29.9) | 36 (18.6–53.9) | 0.22 |  |  |
   Positive | 19 (13.1–24.8) | 26 (12.3–39.7) |  |  |  |
Histology | Â | Â | Â | Â | Â |
   Adenocarcinoma | 28 (22.1–33.8) | 31 (23.1–38.8) | 0.0002 | 5.2 (1.002–29) | 0.05 |
   *Others | 7.8 (3.9–11.7) | 29 (3.5–54.4) |  |  |  |
CEA ≥ 40 ng/mL |  |  |  |  |  |
   Negative | 12 (8–15.9) | 24 (11.8–35.3) | <0.001 | 11.4 (1.7–74) | 0.01 |
   Positive | 61 (45.4–76.8) | 61 (45.4–76.8) |  |  |  |
EGFR*** | Â | Â | Â | Â | Â |
   Positive | 57 (56.6–57.3) | 57 (56.6–57.3) | 0.2 |  |  |
   Negative | 45 (44.6–45.3) | 45 (44.6–45.3) |  |  |  |